Literature DB >> 28127626

Comments on Kamimura et al.: significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients.

S J Fu1,2,3,4, Z F Sheng5,6,7.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28127626     DOI: 10.1007/s00198-016-3867-1

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  7 in total

1.  Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Authors:  Dennis M Black; Ann V Schwartz; Kristine E Ensrud; Jane A Cauley; Silvina Levis; Sara A Quandt; Suzanne Satterfield; Robert B Wallace; Douglas C Bauer; Lisa Palermo; Lois E Wehren; Antonio Lombardi; Arthur C Santora; Steven R Cummings
Journal:  JAMA       Date:  2006-12-27       Impact factor: 56.272

2.  Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial.

Authors:  Ann V Schwartz; Douglas C Bauer; Steven R Cummings; Jane A Cauley; Kristine E Ensrud; Lisa Palermo; Robert B Wallace; Marc C Hochberg; Adrianne C Feldstein; Antonio Lombardi; Dennis M Black
Journal:  J Bone Miner Res       Date:  2010-05       Impact factor: 6.741

Review 3.  Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.

Authors:  Prashanth Peddi; Maria A Lopez-Olivo; Gregory F Pratt; Maria E Suarez-Almazor
Journal:  Cancer Treat Rev       Date:  2012-08-13       Impact factor: 12.111

Review 4.  Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2013-10-01       Impact factor: 6.741

5.  The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT).

Authors:  Dennis M Black; Ian R Reid; Jane A Cauley; Felicia Cosman; Ping Chung Leung; Peter Lakatos; Kurt Lippuner; Steven R Cummings; Trisha F Hue; Amitava Mukhopadhyay; Monique Tan; R Paul Aftring; Richard Eastell
Journal:  J Bone Miner Res       Date:  2015-05       Impact factor: 6.741

6.  Clinician's Guide to Prevention and Treatment of Osteoporosis.

Authors:  F Cosman; S J de Beur; M S LeBoff; E M Lewiecki; B Tanner; S Randall; R Lindsay
Journal:  Osteoporos Int       Date:  2014-08-15       Impact factor: 4.507

7.  Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients.

Authors:  M Kamimura; Y Nakamura; S Ikegami; S Uchiyama; H Kato; A Taguchi
Journal:  Osteoporos Int       Date:  2016-09-20       Impact factor: 4.507

  7 in total
  1 in total

1.  Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients: response to comments.

Authors:  M Kamimura; Y Nakamura; S Ikegami; S Uchiyama; H Kato; A Taguchi
Journal:  Osteoporos Int       Date:  2017-01-27       Impact factor: 4.507

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.